Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Cymbalta
2. Duloxetine
3. Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987
4. Duloxetine Hcl
5. Duloxetine, (+)-isomer
6. Hcl, Duloxetine
7. Hydrochloride, Duloxetine
8. Ly 227942
9. Ly 248686
10. Ly-227942
11. Ly-248686
12. Ly227942
13. Ly248686
14. N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine
15. N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide
1. 136434-34-9
2. Duloxetine Hcl
3. Cymbalta
4. (s)-duloxetine Hydrochloride
5. Ariclaim
6. Xeristar
7. (s)-n-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine Hydrochloride
8. Duloxetine Hydrochloride [usan]
9. Duloxetine Mylan
10. Duloxetine (hydrochloride)
11. Ly248686 Hcl
12. Ly-248686 Hcl
13. Nsc-759112
14. Cpd000469136
15. Duloxetine (as Hydrochloride)
16. Chebi:31526
17. (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine;hydrochloride
18. 9044sc542w
19. Yentreve (tn)
20. (+)-(s)-n-methyl-gamma-(1-naphthyloxy)-2-thiophenepropylamine Hydrochloride
21. Dsstox_cid_26443
22. Dsstox_rid_81618
23. Dsstox_gsid_46443
24. Duloxetine Boehringer Ingelheim
25. Methyl[3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine Hydrochloride
26. (+)-(s)-n-methyl-.gamma.-(1-naphthyloxy)-2-thiophenepropylamine Hydrochloride
27. (s)-n-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine Hcl
28. Smr000469136
29. Dulane 20
30. Cas-136434-34-9
31. Ncgc00164559-01
32. C18h19nos.hcl
33. Unii-9044sc542w
34. Ly 248686 Hcl
35. Cymbalta (tn)
36. Duloxetina Cloridrato
37. Duloxetine Hydrochlorise
38. Duloxetine Lilly
39. Cloridrato De Duloxetina
40. Clorhidrato De Duloxetina
41. Chlorhydrate De Duloxetine
42. Duloxetine Hcl (cymbalta)
43. Mls001401452
44. Mls006010054
45. (s)-duloxetine (hydrochloride)
46. Duloxetine Hydrochloride- Bio-x
47. Chembl1200328
48. Dtxsid9046443
49. Duloxetine Hydrochloride Solution
50. Duloxetine For System Suitability
51. Hy-b0161a
52. Pharmakon1600-01505387
53. Ly-248686 Hydrochloride
54. Amy12420
55. Duloxetine Hydrochloride (jan/usp)
56. Tox21_112188
57. Ac-924
58. Duloxetine Hydrochloride [mi]
59. Mfcd06407958
60. Nsc744012
61. Nsc759112
62. S2084
63. Duloxetine Hydrochloride [jan]
64. (3s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine Hydrochloride
65. Akos016340453
66. Tox21_112188_1
67. Ccg-101106
68. Cs-1993
69. Ks-1168
70. Nc00356
71. Nsc 759112
72. Nsc-744012
73. (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Hydrochloride
74. 2-thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, Hydrochloride, (gammas)-
75. 2-thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, Hydrochloride, (s)-
76. Duloxetine Hydrochloride [mart.]
77. Duloxetine Hydrochloride [usp-rs]
78. Duloxetine Hydrochloride [who-dd]
79. Ncgc00164559-03
80. (s)-(+)-duloxetine Hydrochloride
81. Bd165546
82. Ly-264453
83. D-170
84. D4223
85. Sw197393-3
86. Duloxetine Hydrochloride [orange Book]
87. (s)-duloxetine Hydrochloride, >=98% (hplc)
88. D01179
89. Duloxetine Hydrochloride [ep Monograph]
90. Duloxetine Hydrochloride [usp Monograph]
91. 434d349
92. Q-102508
93. Duloxetine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
94. (+)-(s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine Hydrochloride
95. Duloxetine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
96. (+)-(s)-n-methyl-3-(1-naphthyloxy)- 3-(2-thienyl)propanamine Hydrochloride
97. (3s)-n-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine Hydrochloride
98. (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amin Hydrochloride.
99. (gammas)-2-thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)hydrochloride (1:1)
100. (gammas)-n-methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine Hydrochloride
101. (s)-(+)-n-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) Propanamine Hydrochloride
102. (s)-(+)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine Hydrochloride
103. 2-thiophenepropanamine, N-methyl-.gamma.-(1-naphthalenyloxy)-, Hydrochloride, (s)-
104. Duloxetine For System Suitability, European Pharmacopoeia (ep) Reference Standard
105. Duloxetine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
106. Duloxetine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 333.9 g/mol |
|---|---|
| Molecular Formula | C18H20ClNOS |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Exact Mass | 333.0954131 g/mol |
| Monoisotopic Mass | 333.0954131 g/mol |
| Topological Polar Surface Area | 49.5 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 312 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Cymbalta |
| PubMed Health | Duloxetine (By mouth) |
| Drug Classes | Antidepressant, Central Nervous System Agent, Neuropathic Pain Agent |
| Drug Label | Cymbalta (Duloxetine Delayed-Release Capsules) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-( )- -methyl--(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The e... |
| Active Ingredient | Duloxetine hydrochloride |
| Dosage Form | Capsule, delayed rel pellets |
| Route | oral; Oral |
| Strength | eq 30mg base; eq 20mg base; eq 60mg base |
| Market Status | Prescription |
| Company | Lilly |
| 2 of 4 | |
|---|---|
| Drug Name | Duloxetine hydrochloride |
| Drug Label | Cymbalta (Duloxetine Delayed-Release Capsules) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-( )- -methyl--(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The e... |
| Active Ingredient | Duloxetine hydrochloride |
| Dosage Form | Capsule, delayed rel pellets; Capsule, delayed release |
| Route | oral; Oral |
| Strength | eq 40mg base; 60mg; 30mg; eq 30mg base; eq 20mg base; eq 60mg base; 20mg |
| Market Status | Tentative Approval; Prescription |
| Company | Wockhardt; Actavis Elizabeth; Breckenridge Pharm; Apotex; Alembic Pharms; Teva Pharms Usa; Aurobindo Pharma; Torrent Pharms; Zydus Pharms Usa; Lupin; Dr Reddys Labs; Sandoz; Sun Pharma Global; Impax Labs |
| 3 of 4 | |
|---|---|
| Drug Name | Cymbalta |
| PubMed Health | Duloxetine (By mouth) |
| Drug Classes | Antidepressant, Central Nervous System Agent, Neuropathic Pain Agent |
| Drug Label | Cymbalta (Duloxetine Delayed-Release Capsules) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-( )- -methyl--(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The e... |
| Active Ingredient | Duloxetine hydrochloride |
| Dosage Form | Capsule, delayed rel pellets |
| Route | oral; Oral |
| Strength | eq 30mg base; eq 20mg base; eq 60mg base |
| Market Status | Prescription |
| Company | Lilly |
| 4 of 4 | |
|---|---|
| Drug Name | Duloxetine hydrochloride |
| Drug Label | Cymbalta (Duloxetine Delayed-Release Capsules) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-( )- -methyl--(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The e... |
| Active Ingredient | Duloxetine hydrochloride |
| Dosage Form | Capsule, delayed rel pellets; Capsule, delayed release |
| Route | oral; Oral |
| Strength | eq 40mg base; 60mg; 30mg; eq 30mg base; eq 20mg base; eq 60mg base; 20mg |
| Market Status | Tentative Approval; Prescription |
| Company | Wockhardt; Actavis Elizabeth; Breckenridge Pharm; Apotex; Alembic Pharms; Teva Pharms Usa; Aurobindo Pharma; Torrent Pharms; Zydus Pharms Usa; Lupin; Dr Reddys Labs; Sandoz; Sun Pharma Global; Impax Labs |
- Treatment of major depressive disorder;
- Treatment of diabetic peripheral neuropathic pain;
- Treatment of generalised anxiety disorder;
- Duloxetine Mylan is indicated in adults.
Duloxetine Lilly is indicated in adults for:
- Treatment of major depressive disorder
- Treatment of diabetic peripheral neuropathic pain
- Treatment of generalised anxiety disorder
Duloxetine Lilly is indicated in adults.
Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI).
Treatment of major depressive disorder.
Treatment of diabetic peripheral neuropathic pain.
Treatment of generalised anxiety disorder.
Cymbalta is indicated in adults.
Treatment of diabetic peripheral neuropathic pain.
Ariclaim is indicated in adults.
Treatment of diabetic peripheral neuropathic pain in adults.
Treatment of chronic pain, Treatment of diabetic neuropathic pain, Treatment of generalised anxiety disorder, Treatment of major depressive disorder, Treatment of stress urinary incontinence
Antidepressive Agents
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Serotonin and Noradrenaline Reuptake Inhibitors
Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS. (See all compounds classified as Serotonin and Noradrenaline Reuptake Inhibitors.)
Dopamine Agents
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)
N06AX21
N06AX21
N06AX21
N06AX21
N06AX21
N06AX21
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
NDC Package Code : 62128-0386
Start Marketing Date : 2004-08-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Lilly Korea Ltd.
Registration Date : 2007-01-25
Registration Number : Su51-3-ND
Manufacturer Name : Evonik Corporation
Manufacturer Address : Tippecanoe Laboratories1650 Lilly Road Lafayette, IN 47909
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
✕ Product Not Available For Sales
NDC Package Code : 55111-859
Start Marketing Date : 2007-02-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.
Certificate Number : CEP 2023-144 - Rev 00
Issue Date : 2024-12-19
Type : Chemical
Substance Number : 2594
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-04-15
Pay. Date : 2022-03-08
DMF Number : 36834
Submission : 2022-03-16
Status : Active
Type : II
Certificate Number : CEP 2012-319 - Rev 01
Issue Date : 2024-06-21
Type : Chemical
Substance Number : 2594
Status : Valid
Registration Number : 302MF10013
Registrant's Address : Cesar Martinell i Brunet 12A, Poligono Rubi Sur, Rubi (Barcelona), Spain
Initial Date of Registration : 2020-01-27
Latest Date of Registration :
NDC Package Code : 71495-0003
Start Marketing Date : 2022-02-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Saehan Pharmaceutical Co., Ltd.
Registration Date : 2015-07-27
Registration Number : Su4098-3-ND
Manufacturer Name : Moehs Cantabra SL_x000D_
Manufacturer Address : Poligono Industrial Requejada, 39313, Polanco, Cantabria, Spain
| Available Reg Filing : ASMF |
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2022-04-15
Pay. Date : 2022-03-08
DMF Number : 36834
Submission : 2022-03-16
Status : Active
Type : II
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-23
Pay. Date : 2013-03-06
DMF Number : 24939
Submission : 2011-05-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21524
Submission : 2008-04-08
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2020-11-17
Pay. Date : 2020-11-10
DMF Number : 20996
Submission : 2007-10-30
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19974
Submission : 2006-11-03
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21485
Submission : 2008-03-31
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2018-02-23
Pay. Date : 2018-02-09
DMF Number : 21478
Submission : 2008-03-29
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21385
Submission : 2008-02-29
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19631
Submission : 2006-07-25
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.
Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.
Certificate Number : CEP 2023-144 - Rev 00
Status : Valid
Issue Date : 2024-12-19
Type : Chemical
Substance Number : 2594
Duloxetine Hydrochloride, Milled, Micronised
Certificate Number : CEP 2012-319 - Rev 01
Status : Valid
Issue Date : 2024-06-21
Type : Chemical
Substance Number : 2594
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
Certificate Number : R1-CEP 2012-217 - Rev 01
Status : Valid
Issue Date : 2022-09-21
Type : Chemical
Substance Number : 2594
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2013-016 - Rev 02
Status : Valid
Issue Date : 2021-07-26
Type : Chemical
Substance Number : 2594

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2014-239 - Rev 00
Status : Valid
Issue Date : 2020-08-28
Type : Chemical
Substance Number : 2594

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2015-166 - Rev 00
Status : Valid
Issue Date : 2021-10-22
Type : Chemical
Substance Number : 2594

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2013-197 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2014-12-01
Type : Chemical
Substance Number : 2594

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2014-297 - Rev 00
Status : Valid
Issue Date : 2021-08-05
Type : Chemical
Substance Number : 2594

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2013-340 - Rev 00
Status : Valid
Issue Date : 2020-11-03
Type : Chemical
Substance Number : 2594

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2015-130 - Rev 01
Status : Expired
Issue Date : 2019-02-12
Type : Chemical
Substance Number : 2594

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Details:
Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Duloxetine Hydrochloride,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2014
Lead Product(s) : Duloxetine Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability Study of Duloxetine Delayed-Relase Capsules 60 mg Under Fed Condition
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2014
Details:
Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Duloxetine Hydrochloride,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2014
Lead Product(s) : Duloxetine Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2014
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ALA-3000 is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Treatment-Resistant.
Lead Product(s): ALA-3000,Escitalopram Oxalate,Sertraline Hydrochloride,Duloxetine Hydrochloride,Venlafaxine
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ALA-3000,Escitalopram Oxalate,Sertraline Hydrochloride,Duloxetine Hydrochloride,Venlafaxine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Ascending Dose Phase 1 Study of ALA-3000
Details : ALA-3000 is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Treatment-Resistant.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 11, 2025

Details:
Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Lead Product(s): Duloxetine Hydrochloride,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 21, 2024

Lead Product(s) : Duloxetine Hydrochloride,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 21, 2024

Details:
Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Duloxetine Hydrochloride,Benztropine
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 30, 2024

Lead Product(s) : Duloxetine Hydrochloride,Benztropine
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.
Lead Product(s): Esketamine Hydrochloride,Duloxetine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Spravato
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 23, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Esketamine Hydrochloride,Duloxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SPRAVATO®▼ (esketamine nasal spray) Data from the Phase 3b ESCAPE-TRD Study Demonstrate Superio...
Details : Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressiv...
Product Name : Spravato
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 23, 2022

Details:
Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain, Postoperative.
Lead Product(s): Duloxetine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 10, 2022

Lead Product(s) : Duloxetine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Duloxetine Impact on Postoperative Pain Control and Outcomes
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 10, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Osteoarthritis, Knee.
Lead Product(s): Duloxetine Hydrochloride,Etoricoxib,Omeprazole
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 25, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Duloxetine Hydrochloride,Etoricoxib,Omeprazole
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomarkers for Prediction of Analgesic Efficacy in Knee OA.
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Citalopram HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder.
Lead Product(s): Citalopram Hydrobromide,Escitalopram Oxalate,Fluoxetine Hydrochloride,Paroxetine Hydrochloride,Sertraline Hydrochloride,Duloxetine Hydrochloride,Venlafaxine
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 02, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Citalopram Hydrobromide, Escitalopram Oxalate, Fluoxetine Hydrochloride, Paroxetine Hydrochloride, Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Citalopram HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 02, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Duloxetine Hydrochloride,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Duloxetine Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results](S)-3-Methyl amino-1-(2-thienyl)-1-propanol
CAS Number : 116539-55-0
End Use API : Duloxetine Hydrochloride
About The Company : Aarti Pharmalabs is generic APIs & Intermediates manufacturing company & small molecule drug substance CDMO and the largest Indian manufacturer of Xanthine Deri...
(S)-N-Methyl-3-hydroxy-3-(2-thienyl)propanamine
CAS Number : 116539-55-0
End Use API : Duloxetine Hydrochloride
About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...
RS-N,N-Dimethyl-3-hydroxy-3-(2-thienyl)-1-propanam...
CAS Number : 13636-02-7
End Use API : Duloxetine Hydrochloride
About The Company : Zeon Pharma Industries India Pvt. Ltd. is an ISO 9001:2015, cGMP, and WHO-GMP certified company with a dedicated manufacturing facility for Bulk Drugs (APIs), p...
S-(+)-N,N- Dimethyl-3-(1-Naphthalenyloxy)-3-(2-thi...
CAS Number : 132335-44-5
End Use API : Duloxetine Hydrochloride
About The Company : Zeon Pharma Industries India Pvt. Ltd. is an ISO 9001:2015, cGMP, and WHO-GMP certified company with a dedicated manufacturing facility for Bulk Drugs (APIs), p...
RS-N,N- Dimethyl-3-(1-Naphthalenyloxy)-3-(2-thieny...
CAS Number : 116817-84-6
End Use API : Duloxetine Hydrochloride
About The Company : Zeon Pharma Industries India Pvt. Ltd. is an ISO 9001:2015, cGMP, and WHO-GMP certified company with a dedicated manufacturing facility for Bulk Drugs (APIs), p...
(S)-(-)N, N-dimethyl-3-hydroxy 3-(2-thieyl)propana...
CAS Number : 132335-44-5
End Use API : Duloxetine Hydrochloride
About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...

(S)-(+) N,N-dimethyl-3-(1-napthalenyloxy)-3- (2_th...
CAS Number : 132335-47-8
End Use API : Duloxetine Hydrochloride
About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...

(S)-3-Chloro-1-(thiophen-2-yl)propan-1-ol
CAS Number : 164071-56-1
End Use API : Duloxetine Hydrochloride
About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...

(S)-3-(Methyamino)-1-(thiophen-2-yl)propan-1-ol
CAS Number : 116539-55-0
End Use API : Duloxetine Hydrochloride
About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...

(S)-3-(DIMETHYLAMINO)-1-(2- THIENYL)-1-PROPANOL
CAS Number : 132335-44-5
End Use API : Duloxetine Hydrochloride
About The Company : Dasami Lab Private Limited incorporated with MCA on 24 July 2015. The Dasami Lab Private Limited is listed in the class of pvtltd company and classified as Non ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Capsule
Grade : Oral
Brand Name : EUDRAGIT® L 100-55
Application : Controlled & Modified Release
Excipient Details : EUDRAGIT® L 100-55 (powder) is used in delayed release coatings to enhance solubility of poorly soluble drugs such as tablets, capsules & granules.
Pharmacopoeia Ref : NA
Technical Specs : NA
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Dosage Form : Tablet
Grade : Oral
Brand Name : EUDRAGIT® L 30 D-55
Application : Film Formers & Plasticizers
Excipient Details : EUDRAGIT® L 30 D-55 (aqueous dispersion) is a delayed release polymer used as coating and film former in tablets, capsules, granules etc.
Pharmacopoeia Ref : NA
Technical Specs : NA
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Dosage Form : Orodispersible Tablet
Grade : Oral, Topical
Application : Disintegrants & Superdisintegrants
Excipient Details : Glycine is used as a disintegrant in solid dosage forms such as orally disintegrating tablets and in topical formulations such as emulsions & creams.
Pharmacopoeia Ref : NA
Technical Specs : Molecular weight: 75.07 g/mol
Ingredient(s) : Glycine Excipient
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Grade : Oral
Category : Coating Systems & Additives, Film Formers & Plasticizers
Brand Name : EUDRAGIT® L 30 D-55
Application : Coating Systems & Additives, Film Formers & Plasticizers
Excipient Details : EUDRAGIT® L 30 D-55 (aqueous dispersion) is a delayed release polymer used as coating and film former in tablets, capsules, granules etc.
Pharmacopoeia Ref : NA
Technical Specs : NA
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Dosage Form : Capsule, Granule / Pellet, Tablet
Grade : Oral
Category : Coating Systems & Additives, Controlled & Modified Release, Solubilizers
Brand Name : EUDRAGIT® L 100-55
Application : Coating Systems & Additives, Controlled & Modified Release, Solubilizers
Excipient Details : EUDRAGIT® L 100-55 (powder) is used in delayed release coatings to enhance solubility of poorly soluble drugs such as tablets, capsules & granules.
Pharmacopoeia Ref : NA
Technical Specs : NA
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Coating Systems & Additives
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Emulsion, Tablet
Grade : Oral, Ophthalmic
Category : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Excipient Details : Hydroxypropyl Methyl Cellulose is used as a film-former, disintegrant, thickener, and emulsifier in tablets, emulsions, and ophthalmic formulations.
Grade : Oral
Category : Coating Systems & Additives, Controlled & Modified Release, Solubilizers
Brand Name : Lumacril L-100D 55
Application : Coating Systems & Additives, Controlled & Modified Release, Solubilizers
Excipient Details : Lumacril L-100D 55 is an anionic copolymer used in delayed & sustained release coatings to enhance solubility for poorly soluble drugs in OSDs.
Pharmacopoeia Ref : USP-NF, Ph.Eur, BP, JP
Technical Specs : NA
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Dosage Form : Tablet
Grade : Oral
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Ecopol L 30 D-55 is used as an enteric/delayed release coating system for drug delivery in the duodenum.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Application : Coating Systems & Additives
Excipient Details : Acrycoat L100 is used as an enteric coated Drug delivery system.
Pharmacopoeia Ref : USP/NF: Methacrylic Acid Copol...
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Application : Coating Systems & Additives
Excipient Details : Acrycoat L100D is used as an enteric coated Drug delivery system.
Pharmacopoeia Ref : USP/NF: Methacrylic Acid Copol...
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Dosage Form : Tablet
Grade : Oral
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Ecopol L100 55 is an enteric/delayed release coating for drug delivery in the duodenum.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Dosage Form : Granule / Pellet, Tablet
Grade : Oral
Category : Fillers, Diluents & Binders, Granulation, Solubilizers
Dosage Form : Tablet
Grade : Oral
Category : Granulation, Lubricants & Glidants, Surfactant & Foaming Agents
Application : Disintegrants & Superdisintegrants
Excipient Details : Crospovidone is used as a disintegrant in solid oral dosage forms such as tablets and capsules.
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Disintegrants & Superdisintegrants, Granulation
Dosage Form : Capsule, Tablet, Topical Film, Transdermal Patch
Grade : Not Available
Category : Controlled & Modified Release, Direct Compression, Granulation
Application : Controlled & Modified Release, Direct Compression, Granulation
Excipient Details : For non-erodible matrices using direct compression, Controlled release matrix. Matrix former in transdermal patches and topical films.
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP-JPE: 80 %...
Technical Specs : Not Available
Ingredient(s) : Lauryl Sulfate
Application : Granulation
Excipient Details : Crospovidone is used as a granulating agent in pharmaceutical formulations such as tablets, granules, and pellets.
Dosage Form : Granule / Pellet, Tablet
Grade : Not Available
Category : Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Granulation
Application : Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Granulation
Excipient Details : Tablets, Granules, Pills, Disintegrants and fillers.
Application : Fillers, Diluents & Binders, Granulation
Excipient Details : Fully Pregel Starch Corn is used as a binder in wet granulation in the manufacturing of tablets.
Brand Name : Sheffield™ Monohydrate 313
Application : Granulation
Excipient Details : Wet Granulation & Capsule Filling
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Application : Fillers, Diluents & Binders, Granulation
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Density- Tapped density- 857 g/l, Bulk density- 589 g/l; Particle...
Ingredient(s) : Lactose Monohydrate
Excipients Web Link
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
84
PharmaCompass offers a list of Duloxetine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Duloxetine Hydrochloride manufacturer or Duloxetine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Duloxetine Hydrochloride manufacturer or Duloxetine Hydrochloride supplier.
A Duloxetine Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Duloxetine Hydrochloride, including repackagers and relabelers. The FDA regulates Duloxetine Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Duloxetine Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Duloxetine Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Duloxetine Hydrochloride supplier is an individual or a company that provides Duloxetine Hydrochloride active pharmaceutical ingredient (API) or Duloxetine Hydrochloride finished formulations upon request. The Duloxetine Hydrochloride suppliers may include Duloxetine Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Duloxetine Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Duloxetine Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Duloxetine Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Duloxetine Hydrochloride DMFs exist exist since differing nations have different regulations, such as Duloxetine Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Duloxetine Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Duloxetine Hydrochloride USDMF includes data on Duloxetine Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Duloxetine Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Duloxetine Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Duloxetine Hydrochloride Drug Master File in Japan (Duloxetine Hydrochloride JDMF) empowers Duloxetine Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Duloxetine Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Duloxetine Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Duloxetine Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Duloxetine Hydrochloride Drug Master File in Korea (Duloxetine Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Duloxetine Hydrochloride. The MFDS reviews the Duloxetine Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Duloxetine Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Duloxetine Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Duloxetine Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Duloxetine Hydrochloride suppliers with KDMF on PharmaCompass.
A Duloxetine Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Duloxetine Hydrochloride Certificate of Suitability (COS). The purpose of a Duloxetine Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Duloxetine Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Duloxetine Hydrochloride to their clients by showing that a Duloxetine Hydrochloride CEP has been issued for it. The manufacturer submits a Duloxetine Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Duloxetine Hydrochloride CEP holder for the record. Additionally, the data presented in the Duloxetine Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Duloxetine Hydrochloride DMF.
A Duloxetine Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Duloxetine Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Duloxetine Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Duloxetine Hydrochloride written confirmation (Duloxetine Hydrochloride WC) is an official document issued by a regulatory agency to a Duloxetine Hydrochloride manufacturer, verifying that the manufacturing facility of a Duloxetine Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Duloxetine Hydrochloride APIs or Duloxetine Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Duloxetine Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Duloxetine Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Duloxetine Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Duloxetine Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Duloxetine Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Duloxetine Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Duloxetine Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Duloxetine Hydrochloride suppliers with NDC on PharmaCompass.
Duloxetine Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Duloxetine Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Duloxetine Hydrochloride GMP manufacturer or Duloxetine Hydrochloride GMP API supplier for your needs.
A Duloxetine Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Duloxetine Hydrochloride's compliance with Duloxetine Hydrochloride specifications and serves as a tool for batch-level quality control.
Duloxetine Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Duloxetine Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Duloxetine Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Duloxetine Hydrochloride EP), Duloxetine Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Duloxetine Hydrochloride USP).